ArticleCureus2025
Primary Clear Cell Adenocarcinoma of the Cervix: A Series of 12 Cases Without Exposure to Diethylstilbestrol.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Clear cell adenocarcinoma of the uterine cervix (CCAUC) is a rare malignancy, historically linked to in utero diethylstilbestrol (DES) exposure. However, several cases have been reported in non-DES-exposed populations, particularly in Asia. This study aimed to evaluate the clinicopathological features, treatment modalities, and outcomes in patients with CCAUC unassociated with DES exposure. Methods We conducted a retrospective analysis of 12 patients diagnosed with CCAUC between 2015 and 2022 at Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan. All diagnoses were confirmed by central pathology review. Patient data included demographics, clinical presentation, staging (FIGO: International Federation of Gynecology and Obstetrics), treatment details, and outcomes. Treatment approaches varied by disease stage and included surgery, chemotherapy, and concurrent chemoradiotherapy (CCRT). Results The mean age at diagnosis was 46.25 years, with most patients being premenopausal. Tumor size exceeded 4 cm in 83.3% of cases, with 50% cases being either stage FIGO IIB or IIIA. A majority (91.7%) received CCRT. The five-year overall survival was 64.3%, and disease recurrence occurred in 25% of patients, with distant metastases being the most common. Conclusions CCAUC in non-DES-exposed women tends to manifest in older age groups with bulky disease. Although treatment strategies are not standardized, primary surgery remains favorable for early-stage disease, while CCRT is appropriate for advanced stages. Given the rarity and poor prognosis of CCAUC, larger prospective studies are warranted to refine treatment guidelines and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.